MedPath

Novo Nordisk A/S

Novo Nordisk A/S logo
🇩🇰Denmark
Ownership
Public
Established
1923-01-01
Employees
63.3K
Market Cap
$602.2B
Website
http://www.novonordisk.com
hcplive.com
·

Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD

SMART trial results presented at Kidney Week 2024 show semaglutide reduces UACR by -52.1% in nondiabetic CKD patients, with sustained effects post-treatment. No significant Cr-eGFR difference observed, but weight and waist circumference reduced. Study explores semaglutide 's potential in kidney and cardiovascular care.

Weight management market continues to grow

The weight management market is rapidly expanding, with SNS Insider projecting a 43.73% annual growth rate through 2032. Major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Roche are entering the market, anticipating a 15-fold increase in obesity drug sales over five years. PlantX Life Inc. has partnered with LIV3 to launch SugarShield , a plant-based weight loss supplement targeting the $5.24bn market. Novo Nordisk's SOUL trial showed oral semaglutide reduced MACE by 14% in type 2 diabetes patients, while Eli Lilly is suing vendors for selling copycat tirzepatide . Viking Therapeutics and Roche are also advancing in obesity drug development.
newswire.ca
·

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

PlantX Life Inc. announces joint venture with LIV3 to launch SugarShield supplement, targeting the $5.24 billion weight loss management market. The supplement aims to boost energy, curb cravings, and simplify weight management without restrictive diets, leveraging PlantX's expertise in branding and digital platforms.
bioworld.com
·

CHMP nods for Korjuny, Alhemo; no, again, for Translarna, masitinib

Catumaxomab, now branded as Korjuny , received a positive opinion from the EMA 's CHMP for treating malignant ascites, marking its return after a decade off the market. Korjuny , a bispecific and trifunctional antibody, engages Epcam on cancer cells and CD3 on T cells, recruiting immune cells to destroy tumor cells. The EMA approval is limited to malignant ascites, but ongoing trials aim to expand its use, including a global phase III trial in advanced gastric cancer.
finance.yahoo.com
·

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials

Veru Inc. will present at ObesityWeek on November 5, 2024, discussing enobosarm 's potential to optimize weight loss. The Phase 2b clinical trial evaluates enobosarm 's safety and efficacy in preserving muscle and augmenting fat loss in sarcopenic obese patients. Topline results are expected in January 2025, with extension study results in Q2 2025.
openpr.com
·

Artificial Intelligence (AI) in Biotechnology Market Industry

The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca , Bristol-Myers Squibb , and Gilead Sciences Inc.
kffhealthnews.org
·

Out Of The Trash Bin: How Cobenfy's Unusual Journey Could Change Pharma

Bristol Myers Squibb 's schizophrenia drug, Cobenfy , approved by FDA after 30-year journey from Eli Lilly 's Alzheimer's drug xanomeline , could inspire future drug discovery.
openpr.com
·

Artificial Intelligence In Medicine Global Market Report 2024: Size, Share, Trends, Forecast to 2033

AI in medicine market to grow from $8.01B in 2023 to $42.11B in 2028 at a CAGR of 39.3%, driven by chronic disease prevalence and digital transformation adoption.
biocentury.com
·

Novo's Phase II miss in obesity oral amps up pressure on BD

Novo Nordisk 's Phase II failure with CB1 blocker monlunabant highlights poor weight loss and neuropsychiatric adverse events, intensifying pressure on the company to acquire an oral obesity therapy.
© Copyright 2025. All Rights Reserved by MedPath